Strategies to Improve Glaucoma Compliance Based on Cross-Sectional Response-Based Data in a Tertiary Healthcare Center: The Glauco-Jung Study

Vishnu S Gupta, Harindersingh Sethi, Mayuresh Naik

ABSTRACT

Purpose: To elucidate compliance rates among glaucoma patients in a tertiary healthcare center, reasons for noncompliance and response-based-solutions to improve compliance in the same cohort.

Materials and methods: In the Glauco-Jung study, a cross-sectional descriptive epidemiological one, information was obtained from 500 patients from 1st January, 2014 to 30th June, 2014. Patients were intercepted at entry point where they get their intraocular pressure (IOP) checked, wherein they were asked to fill an exhaustive questionnaire. At the same setting, they were also asked to demonstrate how they (or their relatives or helpers) instill eyedrops, following which any irregularities were brought to notice and corrected. Finally, they were also asked any suggestions to improve compliance to medications.

Noncompliance rates were determined based on the number of patients who did not instill anti-glaucoma medications as per prescribed dosage or frequency schedule. Noncompliance rates were then evaluated by the Chi-square test for any association with distributions based on various parameters.

Results: In case of a positive association, correlation coefficient was further calculated to know the strength of this association. No association was observed in distributions based on diet, associated co-morbidities, daily dosage frequency and side-effects experienced by patients. Positive association was noted in distributions based on age, sex, duration of treatment, social structure and number of medications (p < 0.05); but correlation coefficients were very weak (c < 0.3). Cost of medications not only had positive association but also had a very strong correlation coefficient (c = 0.9188), proving that cost of medications had a modest bearing on compliance rates.

Conclusion: The Glauco-Jung study concluded that besides availability of medications at reasonable cost, simplification of treatment regimen and interactive health education appear to be the most important factors for improving compliance so that patients do not feel guilty or inadequate because they have problems while administering their eyedrops.

Keywords: Compliance, Cost of medications, Glaucoma.

How to cite this article: Gupta VS, Sethi H, Naik M. Strategies to Improve Glaucoma Compliance Based on Cross-Sectional Response-Based Data in a Tertiary Healthcare Center: The Glauco-Jung Study. J Curr Glaucoma Pract 2015;9(2):38-46.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Noncompliance with medical therapy has long been recognized as an important limiting factor in the medical management of many chronic diseases. Patients with glaucoma who have lower rates of compliance are presumed to be at greater risk of developing progressive visual loss. Rates of compliance with therapeutic regimens for chronic diseases, including glaucoma, may be as low as 50%; and noncompliance has been associated with an increase in hospital admissions, length of stay, and healthcare costs.

The present Glauco-Jung study is an effort to elucidate the compliance rates among glaucoma patients and the reasons for noncompliance as well as goes a step further in providing possible solutions to improve compliance in the same cohort.

MATERIALS AND METHODS

Information was obtained from 500 patients attending the speciality glaucoma clinic from 1st January, 2014 to 30th June, 2014. The patients were intercepted at the entry point where they get their intraocular pressure (IOP) checked, wherein they were asked to fill a questionnaire. The questions that were used explored the patients’ knowledge of their condition and its treatment, whether their compliance was good or bad and the reasons for this, how they administered their drops, any problems encountered, and whether they would welcome a compliance aid if a suitable one was available. At the same setting, they were also asked to demonstrate how they (or their relatives or helpers) instill eyedrops, following which any irregularities were brought to notice and corrected. Finally, they were also asked any suggestions to improve compliance to medications.

Noncompliance rates were determined based on the number of patients who did not instill anti-glaucoma medications as per prescribed dosage or frequency schedule.
medications as per prescribed dosage or frequency schedule. Noncompliance rates were then evaluated by the Chi-square test for any association with distributions based on various parameters.

RESULTS

Even though females reporting to the glaucoma clinic outnumbered males, the difference was not statistically significant \((p = 0.15)\). There was a statistically significant difference \((p = 0.053)\) in sex distribution of compliance, wherein a greater proportion of males were non-compliant as compared to females. However, the correlation, as such, was very weak \((\text{correlation coefficient } = 0.123)\) (Table 1 and Graph 1).

The major chunk was, however, formed by the age group 41 to 60 years, i.e. the so called ‘economically-productive-age-group’. This was the age group where our machinery to increase compliance, should be targeted (Table 2 and Graph 2).

Age was a statistically significant factor affecting compliance \((p < 0.0001)\). However, there was only a weak correlation between age and noncompliance \((c = 0.277)\), indicating that increasing age did not affect compliance adversely (Table 3 and Graph 3).

Urban population in Delhi shows a preference of non-vegetarian diet while more than half of those presenting to the glaucoma clinic agreed to have had alcohol intake \((60–180 \text{ ml})\) more than twice a month. However, compliance rates were not significantly affected \((p = 0.1551)\) by diet, alcohol and tobacco consumption (Table 4 and Graphs 4 and 5).

| Table 1: Tabulated sex-wise distribution of noncompliant patients |
|---------------------------------------------------------------|
| Patients forgetting to instill eyedrops | Never | Once a week | Twice a week | More than twice a week | Total |
| Males | 106 92 23 8 229 |
| Females | 157 79 26 10 271 |
| Total | 263 171 49 18 500 |

| Table 2: Tabulated age-wise distribution of patients |
|-----------------------------------------------|
| Age (years) | Males | Females | Total |
| 0–20 | 7 4 11 |
| 21–40 | 27 19 46 |
| 41–60 | 127 167 294 |
| 61–80 | 68 81 149 |
| Total | 229 271 500 |

| Table 3: Age-wise distribution of noncompliant patients |
|---------------------------------------------------------------|
| Patients forgetting to instill eyedrops | Never | Once a week | Twice a week | More than twice a week | Total |
| 0–20 years | 9 2 10 0 11 |
| 21–40 years | 27 11 6 2 6 |
| 41–60 years | 179 82 24 9 294 |
| 61–80 years | 47 76 19 7 149 |
| Total | 262 171 49 18 500 |

| Graph 1: Graphical sex-wise distribution of noncompliant patients |
|---------------------------------------------------------------|

| Graph 2: Graphical age-wise distribution of patients |

| Graph 3: Graphical age-wise distribution of noncompliant patients |
The greatest number of patients following up regularly for glaucoma clinic evaluation were those who were diagnosed recently, i.e. within 1 to 5 years. However, duration of treatment apparently did not have any significant bearing on patient compliance ($p = 0.3$) (Table 5 and Graph 6). Statistical analysis of noncompliant patients against their duration under treatment showed that patients were highly compliant initially during their course of treatment, while they tended to become noncompliant ($p < 0.001$) as they became chronic visitors of the glaucoma clinic. However, correlation coefficient was quite weak ($c = 0.276$), thus, proving that it could not be generalized that chronic glaucoma patients became noncompliant over time (Table 6 and Graph 7).

All patients screened for any associated medical disorders were then referred to respective medical specialty clinics and urged to follow-up and comply with their medications. Patients compliant with their medications for medical disorders generally ended up being compliant for their medications for ophthalmic disorders as well. Unfortunately, this could not be statistically proved ($p = 0.9$) (Tables 7 and 8, Graph 8).

Since Indian social structure is adverse to females, illiteracy and unemployment were far more abundant in females as compared to males (Table 9 and Graph 9). Statistical analysis proved that illiterate and unemployed patients were less motivated to comply ($p < 0.001$) with...
treatment as compared to their literate and employed counterparts. However, correlation was still weak enough (c = 0.221) to suggest that literacy could definitely ensure patient compliance (Table 10 and Graph 10). Greater the number of medications that patients were started on, greater was the tendency to forget instilling some of them, and hence greater was their noncompliance (p = 0.0016). However, weak correlation (c = 0.225) suggested that there were a good number of motivated patients who were on multiple medications and were yet compliant enough (Fig. 1, Table 11 and Graph 11).

Even though patients themselves claimed that it was difficult to adhere to multiple dosage timings each day and that they found it easier to comply to single dose frequency, the results could not be proven to be statistically significant (p = 0.06) (Fig. 2, Table 12, Graph 12). Analysis of relationship between monthly cost of medications and irregularities in buying medications proved that their correlation was statistically significant (p = 0.0274). A highly positive correlation coefficient

Table 7: Tabulated distribution of patients with associated co-morbidities

| Associated co-morbidity | No. of patients |
|-------------------------|-----------------|
| Hypertension            | 374             |
| Diabetes                | 342             |
| Asthma                  | 62              |
| Thyroid disorders       | 18              |

Graph 7: Graphical distribution of noncompliant patients based on duration under treatment

Graph 8: Graphical distribution of noncompliant patients with associated co-morbidities

Table 8: Tabulated distribution of noncompliant patients with associated co-morbidities

| Patients forgetting to instill eyedrops | Never | Once a week | Twice a week | More than twice a week | Total |
|----------------------------------------|-------|-------------|--------------|------------------------|-------|
| Hypertensives                          | 173   | 119         | 63           | 19                     | 374   |
| Diabetics                              | 165   | 112         | 51           | 14                     | 342   |
| Asthmatics                             | 28    | 21          | 10           | 3                      | 62    |
| Thyroid patients                       | 8     | 6           | 3            | 1                      | 18    |

Graph 9: Graphical distribution of patients based on Kuppuswamy classification of social structure in India

Table 9: Tabulated distribution of patients based on Kuppuswamy classification for social structure in India

| Kuppuswamy classification | Males | Females |
|---------------------------|-------|---------|
| Highly skilled professional | 10    | 18      |
| Semi-skilled professional  | 68    | 57      |
| Clerk, shop owner, farm owner | 56    | 11      |
| Skilled worker            | 19    | 13      |
| Semi-skilled worker       | 27    | 19      |
| Unskilled                 | 13    | 34      |
| Unemployed                | 23    | 119     |
| Total                     | 229   | 271     |
of 0.9188 suggested that as monthly cost of medications increased, patients became more irregular in buying them. In fact, this was the most important observation in the study. Hence, there is an urgent need to provide as many of the most effective anti-glaucoma medications at government dispensaries at highly subsidized rates (Table 13).

Patients who had had exacerbations of acute or chronic glaucoma, or who had undergone either laser peripheral iridectomy or glaucoma filtering surgery were more prone to remain compliant on their medications as compared to others. Also, only 51% patients knew they had glaucoma, i.e. 49% were unaware of this fact despite being on regular follow-up to the glaucoma clinic. In fact, 34% patients knew that they had glaucoma but had no clue of what glaucoma was or its adverse visual consequences. Hence, compliance was significantly increased ($p = 0.0051$) among patients after they were explained about glaucoma and the need for medications as well as their compliance to it (Tables 14 and 15, Graph 13). The most common side-effects experienced were redness, burning and itching. However, a meager number of patients were found to discontinue their medications without seeking medical advice. Rest patients were comfortably relieved off their discomfort with lubricants and decongestants (Tables 16 and 17).

**Table 10: Tabulated distribution of noncompliant patients based on Kuppuswamy classification for social structure in India**

| Patients forgetting to instill eyedrops | Kuppuswamy score > 6 | Kuppuswamy score 1–5 | Total |
|----------------------------------------|-----------------------|----------------------|-------|
| Never                                  | 113                   | 149                  | 262   |
| Once a week                            | 41                    | 130                  | 171   |
| Twice a week                           | 10                    | 39                   | 49    |
| More than twice a week                 | 2                     | 16                   | 18    |

**Table 11: Tabulated distribution of noncompliant patients based on number of medications**

| Patients forgetting to instill eyedrops | Single medication | Two medications | Three medications | Four medications | Total |
|----------------------------------------|-------------------|-----------------|-------------------|------------------|-------|
| Never                                  | 111               | 95              | 40                | 16               | 191   |
| Once a week                            | 60                | 65              | 28                | 18               | 176   |
| Twice a week                           | 16                | 13              | 11                | 9                | 84    |
| More than twice a week                 | 4                 | 3               | 5                 | 6                | 49    |

**Table 12: Tabulated distribution of noncompliant patients based on number of medications**

| Patients forgetting to instill eyedrops | Single medication | Two medications | Three medications | Four medications | Total |
|----------------------------------------|-------------------|-----------------|-------------------|------------------|-------|
| Never                                  | 111               | 95              | 40                | 16               | 191   |
| Once a week                            | 60                | 65              | 28                | 18               | 176   |
| Twice a week                           | 16                | 13              | 11                | 9                | 84    |
| More than twice a week                 | 4                 | 3               | 5                 | 6                | 49    |

**Miscellaneous Results (Figs 3 to 5)**

Based on the questionnaire, the Glauco-Jung study reiterated nine most important reasons for noncompliance of eyedrops, in descending order of importance and frequency (correlated to number of patients stating it as their reason for noncompliance):
Table 12: Tabulated distribution of noncompliant patients based on dosage frequency

| Patients forgetting to instill eyedrops | Never | Once a week | Twice a week | More than twice a week | Total |
|----------------------------------------|-------|-------------|--------------|------------------------|-------|
| Once daily dosing                       | 139   | 89          | 20           | 7                      | 255   |
| Twice daily dosing                      | 92    | 59          | 16           | 6                      | 173   |
| Thrice daily dosing                     | 31    | 21          | 12           | 4                      | 68    |
| Four times daily dosing                 | 0     | 2           | 1            | 1                      | 4     |
| Total                                  | 262   | 171         | 49           | 18                     | 500   |

Graph 12: Graphical distribution of noncompliant patients based on dosage frequency

- To difficult to follow the complex regimen.
- Unpleasant outcomes or side-effects.
- Too expensive.
- Lack of trust that the eyedrops really work.
- Blinking too much: Discussion with patients indicated that lack of confidence was a major factor, particularly fear of prodding the eye. As a result, the bottle was
often held too far from the eye, making the aim more difficult and encouraging the blink reflex.

- Cannot remember whether drops were put.
- Too hard to squeeze the bottle just right, especially after refrigeration.
- Too hard to stay on target either because of poor visibility of dropper tip or shaky hands.
- No assistance for old aged people to put the eyedrops.

There also exists a certain minimal amount of KAP-GAP among glaucoma patients. The ‘KAP-GAP’ refers to the gap between knowledge, attitudes and practice; and is not specific to any age group, gender, community, region or population. It is both real and resilient, and has long been concerned about a persistent gap which exists when knowledge and favorable attitude do not lead toward adoption of a practice. In spite of the fact that the patients knew that they had glaucoma, and that discontinuation or irregularity of eyedrops would lead to progressive visual loss, there were 1.8% (8/500) patients who were noncompliant for untenable reasons.

**DISCUSSION**

Most meta-analyses yielding cost-benefit ratios, that harness measures of medical usage, have been tampered by the lack of certain consistency in standards relating
to definitions and quantifications used to describe the ‘concepts of drug compliance’. Health outcomes analysts need practical and operationally useful definitions that would help in standardizing the available results, in quantifying a common benchmark for comparing and amalgamating results, and for assisting the development of potent and efficient intervention strategies to upgrade patient drug compliance. The medication compliance and persistence work group of the international society for pharmaco-economics and outcomes research (ISPOR) formulated definitions for compliance and persistence during 3 years of international review and discussion. Compliance is, thereby defined as ‘the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen’, and thus refers to the act of conforming to the recommendations made by the provider with respect to timing, dosage and frequency of medication taking. Persistence may be defined as ‘the duration of time from initiation to discontinuation of therapy’.

Untreated glaucoma ensures progressive damage to the optic nerve, along with progressive visual field defects even including loss of the final surviving ‘island of vision’ and eventually, blindness. Even then, the single most influential deterrent to the successful arrest of glaucoma progression is poor patient compliance with the treatment regimen. Since glaucoma produces few symptoms, there is meager motivation for patients to be consistent with treatment; especially when in the initial stages, when vision-threatening complications have not begun, the only symptoms experienced would be the side-effects of the medication. The aim of therapy for glaucoma is to preserve vision with minimal side-effects and inconvenience.

A major decisive factor of compliance with anti-glaucoma treatment is patient’s knowledge of having glaucoma and the insight regarding the potential for blindness: the more grave their visual loss, the more probable it is that patients will comply with drug schedule as medicated. Compliance is further restrained by the physical ineptitude of patients to use eyedrops adequately, with difficulty expelling the drop from the vial, instilling the drop correctly, and blinking while insertion. Such technical difficulties are referred to as ‘discompliance’. As patients were hesitant to bring up these hindrances with healthcare personnel, the medical fraternity involved with researching ways of bettering patient compliance, were pretty uninformed of the hindrances associated with as meager a task as eye drop instillation. Discompliance is even less realized and admitted than noncompliance. Perceptions about patient compliance, and hence remedies for noncompliance including alternative drug combinations or dosage schedules, are often based on clinical judgments and measurements of IOP, weight of drug vial when the patient reports for follow-up, investigative reports as well as the ophthalmologist’s subjective opinion of the patient. However, noncompliant patients cannot be identified precisely based on these grounds. In addition, there exists only a fairly limited correlation between the ophthalmologists’ presumptions about patient’s compliance and the results of monitoring. Since, these measures are not capable of accurately indicating patient compliance, an eyedrop monitor is required for identification of patients who default from therapy. Using an unobtrusive eyedrop monitor as an objective measure, Kass et al found considerable over-reporting of compliance with glaucoma medication in an interview situation.

**The Glauco-Jung study:**

**Strategies to Improve Compliance**

Clinical outcomes of treatment are affected not only by how much patients adhere to their prescriptions but also by how long they take their drugs as per dosage schedule. Thus, compliance and persistence should be defined and quantified separately to characterize medication-taking behavior comprehensively. Progression of the disease often results in addition of more efficacious or more potent drugs to the already existing drug combination, which may be inappropriate and unnecessary if the progression is due to noncompliance rather than to treatment failure. In addition, necessary glaucoma surgery may be reviewed if noncompliant patients have an IOP at clinic visits that is fairly low as compared to their degree of noncompliance resulting from instilling the medication only during the preceding hours.

- **Patient education:** The usefulness of a 6-minute video-tape in educating 98 patients with glaucoma about their disease as evaluated by Rosenthal et al showed that patients knowledge was not only significantly improved immediately after viewing (p < 0.001) but even after 6 months, patients with glaucoma retained more knowledge of the disease than the controls.
- **Regimen improvisation:** Streamlining a regimen to the patient’s lifestyle.
- **Fixed drug combinations:** Interfere significantly less with daily life in terms of activity limitations and side-effects.
- **Decreasing frequency of dosage:** Patients report significantly fewer missed doses while using once daily preparations as against twice daily preparations of the same drug in another formulation, suggesting that, when appropriate, patients appreciate having their therapy simplified.
• **Compliance aids:** Xal-Ease dispenser from Pfizer for latanoprost products. ‘Eyot’ dispensers available from Alcon for travoprost products. Opticare and Opticare arthro dispensers are designed for people whose hands shake, or have difficulty placing or squeezing the bottle. The Unidoser (Mystic pharmaceuticals) uses a patient-replaceable cartridge system to deliver metered unit doses of ophthalmic medication to the ocular surface. Allergan’s Lumigan compliance aid features a light timed to flash and an optional audible alarm.

• **Tending to possible side-effects:** An emergent advance in therapy is a device that can turn medication into a mist rather than a drop, which is being developed by Optimyst systems (West Islip, New York). This may circumvent the squeamishness some patients have about taking eyedrops.

**CONCLUSION**

The Glauco-Jung study concluded that no doubt the barrier to free communication can be broken down if ophthalmologists take a lead. There is probably also a need for an ‘awareness campaign’ aimed at patients, so that they do not feel guilty or inadequate because they have problems while administering their eyedrops. Simplification of the treatment regimen and interactive health education appear to be the most important factors for improving compliance. The availability of a suitable device will also probably help patients achieve safe administration and improve compliance.

**REFERENCES**

1. Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med 1979 Jun;139(6):627-628.
2. Kass MA. Compliance and prognosis in glaucoma. Arch Ophthalmol 1985 Apr;103(4):504.
3. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy. Am J Ophthalmol 1986 May;101(5):524-530.
4. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed: a novel assessment technique. JAMA 1989 Jun;261(22):3273-3277.
5. Grant A. A cross-sectional, descriptive study to measure: Knowledge, attitudinal and behavioural effects which a positive diagnosis of glaucoma may have on affected patients of the Eye [Internet]. St. Andrew, Jamaica: April-May 2010. Available at: http://www.eyecarecaribbean.com/vision-2020-caribbean/glaucoma-study-fish-april-may-2010-jamaica.
6. Hasford, J. Compliance in Medical Practice and Clinical Trials. Biometric issues in measuring and analysing partial compliance in clinical trials. New York: Raven Press; 1991. p. 265-281.
7. Burrell A, Wong P, Ollendorf DA, Fuldeore MJ, Roy A, Fairchild CJ, Cramer JA. PHP46 Defining compliance/ adherence and persistence: ISPOR Special Interest Working Group. Value Health 2005 Nov;8(6):A194-A195.
8. Sclar DA. Improving medication compliance: a review of selected issues. Clin Ther 1991 Jul-Aug;13(4):436-440.
9. Sclar DA, Skaer TL, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Effectiveness of the C Cap in promoting prescription refill compliance among patients with glaucoma. Clin Ther 1991 May-Jun;13(3):396-400.
10. Ashburn FS Jr, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol 1980 Jan-Feb;24(4):237-238.
11. Sverrisson T, Gross R, Pearson J, Rusk C, Adamsons I. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group. J Glaucoma 1999 Oct;8(5):315-324.
12. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of noncompliance by patients prescribed eyedrops. Br J Ophthalmol 1990 Aug;74(8):477-480.
13. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986 May;101(5):515-523.
14. Granström PA. Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects. Br J Ophthalmol 1982 Jul;66(7):464-470.
15. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol 1983 Dec;28 Suppl:252-257.
16. Rosenthal AR, Zimmerman JE, Tanner J. Educating the glaucoma patient. Br J Ophthalmol 1983 Dec;67(12):814-817.